CHAARTED (E3805)
The first trial to show chemotherapy at the start of hormone therapy prolongs life in metastatic prostate cancer.
790 men; OS 57.6 vs 44.0 months overall (HR 0.61); benefit confined to high-volume disease in long-term follow-up.
Setting
Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT
Phase
Phase 3
Sponsor
ECOG-ACRIN
Registry
Headline result
OS HR 0.61 overall; high-volume HR 0.63; low-volume no benefit.
Reported
2015
Enrolled
790
Replication
Replicated by STAMPEDE arm C; benefit concentrated in high-volume disease.
In plain words
What these results mean for people, not percentages
Overall survivalprimarysurvival endpoint
- Median 57.6 vs 44 months with ADT + docetaxel compared with ADT alone; about 13.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 39 percent lower chance of the event at any given time (hazard ratio 0.61, likely range 0.47 to 0.8).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
790 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | ADT + docetaxel | 397 | 57.6 months | 0.61 (0.47–0.8) | <0.001 | link |
| ADT alone | 393 | 44 months |
Replication
Replicated by STAMPEDE arm C; benefit concentrated in high-volume disease.Pages like this
not linked directly; found by shared links- TrialARASENS
Shares Docetaxel, Prostate cancer.
- TrialPEACE-1
Shares Docetaxel, Prostate cancer.
- PersonNicholas James
Shares Docetaxel, Prostate cancer.
- TrialSTAMPEDE
Shares Docetaxel, Prostate cancer.